APTO News and Press, Aptose Biosciences Inc. From 06/03/19

SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares at a price to t...

I’ve tried to go to some lengths in the past to emphasize the risks that come with an investment in Aptose Biosciences ( APTO ) – a small biotech that has only recently seen its two lead compounds go into the clinic. Not only is there the ever-present risk of clinical trial fai...

SAN DIEGO and TORONTO, May 31, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of ...

Aptose Biosciences (NASDAQ: APTO ) has priced its public offering of 10M common shares at $1.85 per share, for gross proceeds of $18.5M. More news on: Aptose Biosciences Inc., Healthcare stocks news, Stocks on the move, Read more ...

J.Jill (NYSE: JILL )  -51%  on Q1 earnings . More news on: J.Jill, Inc., Aptose Biosciences Inc., Eltek Ltd., Stocks on the move, Read more ...

SAN DIEGO and TORONTO, May 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 10,000,000 common shares at a price of $1...

SAN DIEGO and TORONTO, May 29, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its Common Shares (the “Offering”). In add...

SAN DIEGO and TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today annou...

With the 2019 Bloom Burton & Co. Healthcare Investor Conference (BBHIC) officially behind us for another year, one thing was made very clear at this year’s two-day event based on the attendance: sentiment in the life science sectors is stronger than ever. In his opening r...

SAN DIEGO and TORONTO, May 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today annou...